Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 10:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Uncontrolled Diabetes Clear all
Completed Phase 4 Interventional Results available

The Effect of Simple Basal Insulin Titration, Metformin Plus Liraglutide for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study

NCT01966978
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetes
Interventions
Metformin, Detemir, Liraglutide, Insulin Aspart
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 21, 2019 · Synced Jul 21, 2026, 10:30 AM EDT
Completed Phase 3 Interventional Results available

Study Assessing Saxagliptin Treatment In Type 2 Diabetic Subjects Who Are Not Controlled With Metformin Alone

NCT00121667
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Saxagliptin + Metformin, Placebo + Metformin, Pioglitazone
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 77 Years
Enrollment
1,462 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
95
States / cities
Anniston, Alabama • Birmingham, Alabama • Calera, Alabama + 92 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2015 · Synced Jul 21, 2026, 10:30 AM EDT
Terminated Not applicable Interventional Results available

Cognitive Behavioral Therapy for African Americans With Uncontrolled Type-2 Diabetes

NCT03562767
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Group-based Cognitive Behavioral Intervention, Web-based Cognitive Behavioral Intervention, Usual Care
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Jul 21, 2026, 10:30 AM EDT
Not listed Phase 2 Interventional

An Add-on Study of MLR-1023 in Adults With Uncontrolled Type 2 Diabetes on Metformin Therapy

NCT03279263
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
MLR-1023, Placebo
Drug · Other
Lead sponsor
Melior Pharmaceuticals
Other
Eligibility
18 Years to 75 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Jul 21, 2026, 10:30 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Use of a Smart-phone Based Medication Adherence Platform to Improve Outcomes in Uncontrolled Non-insulin Dependent Diabetes Among Veterans

NCT05789706
View directory record Official record
Conditions
Diabetes, Diabete Type 2
Interventions
Dayamed Arthur a novel intelligent medication adherence platform
Behavioral
Lead sponsor
VA Sierra Nevada Health Care System
Federal
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Reno, Nevada
Source: ClinicalTrials.gov public record
Updated Mar 28, 2023 · Synced Jul 21, 2026, 10:30 AM EDT
Completed Phase 3 Interventional Results available

A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone

NCT03954834
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
28
States / cities
Huntington Park, California • Los Angeles, California • Montclair, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2021 · Synced Jul 21, 2026, 10:30 AM EDT
Completed Phase 3 Interventional

Study Comparing Muraglitazar With Glimepiride in Type 2 Diabetics Who Are Not Controlled With Metformin Alone

NCT00095030
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
muraglitazar
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,752 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
108
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 105 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2010 · Synced Jul 21, 2026, 10:30 AM EDT
Completed Phase 4 Interventional Results available

Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes Mellitus

NCT05114590
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Insulin glargine/Lixisenatide
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
18
States / cities
Canyon Country, California • Huntington Park, California • Lomita, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Jul 21, 2026, 10:30 AM EDT
Completed Phase 4 Interventional Results available

A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)

NCT02451137
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin glargine, 300 U/ml, Insulin glargine, 100 U/ml, Insulin detemir, Background Therapy
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
3,304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
407
States / cities
Birmingham, Alabama • Gulf Shores, Alabama • Guntersville, Alabama + 304 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Jul 21, 2026, 10:30 AM EDT
Completed Phase 3 Interventional Results available

Study of BMS-477118 as Monotherapy With Titration in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise

NCT00316082
View directory record Official record
Conditions
Diabetes
Interventions
Saxagliptin, Placebo, metformin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 77 Years
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
51
States / cities
Columbiana, Alabama • Haleyville, Alabama • Mesa, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2015 · Synced Jul 21, 2026, 10:30 AM EDT
Completed Phase 1Phase 2 Interventional Results available

HORNBILL: A Study to Test Different Doses of BI 764524 in Patients Who Have Had Laser Treatment for a Type of Diabetic Eye Disease Called Diabetic Retinopathy With Diabetic Macular Ischemia

NCT04424290
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
BI 764524, Sham control of BI 764524
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
13
States / cities
Dothan, Alabama • Beverly Hills, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 21, 2024 · Synced Jul 21, 2026, 10:30 AM EDT
Completed Phase 4 Interventional Results available

Linagliptin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes

NCT01512979
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
metformin, linagliptin, metformin placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
29
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Chino, California + 26 more
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Jul 21, 2026, 10:30 AM EDT
Completed Not applicable Interventional Results available

Insulin Dosage Software Program for People With Type 1 and Type 2 Diabetes

NCT01170208
View directory record Official record
Conditions
Diabetes, Insulin
Interventions
insulin dose software
Device
Lead sponsor
HealthPartners Institute
Other
Eligibility
21 Years to 70 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 26, 2020 · Synced Jul 21, 2026, 10:30 AM EDT
Completed No phase listed Observational

Telemedicine Continuous Remote Monitoring of Adults With Uncontrolled Diabetes Mellitus

NCT05161793
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
Tele-Monitor DM
Device
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Jul 21, 2026, 10:30 AM EDT
Completed Phase 3 Interventional Results available

A Study Assessing Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise

NCT00374907
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Saxagliptin, Placebo, Metformin (blinded), Metformin (open-label)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
3
States / cities
San Diego, California • Baton Rouge, Louisiana • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 6, 2015 · Synced Jul 21, 2026, 10:30 AM EDT
Completed Not applicable Interventional

Efficacy and Safety of Frequently Modified Intensive Insulin

NCT01014832
View directory record Official record
Conditions
Diabetes
Interventions
Intensive insulin therapy
Drug
Lead sponsor
Hygieia, Inc
Industry
Eligibility
25 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Paramus, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 16, 2009 · Synced Jul 21, 2026, 10:30 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Health Literacy Intervention for African Americans With Diabetes

NCT03925948
View directory record Official record
Conditions
Uncontrolled Diabetes
Interventions
PLAN 4 Success-Diabetes
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Jul 21, 2026, 10:30 AM EDT
Withdrawn Phase 4 Interventional

Efficacy of Exenatide-LAR and Dapagliflozin in Overweight/Obese, Insulin Treated Patients With Type 2 Diabetes

NCT02811484
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Exenatide-LAR plus Dapagliflozin placebo, Exenatide-LAR plus Dapagliflozin, Insulin Titration, Behavioral Therapy
Drug · Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Jul 21, 2026, 10:30 AM EDT
Terminated Phase 4 Interventional

Comparison of Neutral Protamine Hagedorn (NPH) and Lantus Based Insulin Regimen in the Management of Hypoglycemia in the Hospitalized Patients in Noncritical Care Setting

NCT02189395
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
NPH and regular insulin, glargine and humalog
Drug
Lead sponsor
Riverside University Health System Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Moreno Valley, California
Source: ClinicalTrials.gov public record
Updated Sep 27, 2017 · Synced Jul 21, 2026, 10:30 AM EDT
Completed Not applicable Interventional

T2D Pilot Study for Patients With Uncontrolled Type 2 Diabetes

NCT06988540
View directory record Official record
Conditions
Diabetes Mellitus, Health Behavior, Diabetes Mellitus, Type 2, Group Meetings
Interventions
Personalized Health Planning Program Administration, Usual Care
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Jul 21, 2026, 10:30 AM EDT
Completed Phase 2 Interventional

Adult Subjects With Uncontrolled Type 2 Diabetes

NCT02317796
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
MLR-1023
Drug
Lead sponsor
Melior Pharmaceuticals
Other
Eligibility
18 Years to 75 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
USA and South Korea, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 25, 2016 · Synced Jul 21, 2026, 10:30 AM EDT
Recruiting Not applicable Interventional

Impact of a Diabetes Education Mobile Web Application on Patients With Uncontrolled Type 2 Diabetes

NCT05893927
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetes Education, Lifestyle Modification
Interventions
Diabetes education web site application
Other
Lead sponsor
The Reading Hospital and Medical Center
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
West Reading, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Jul 21, 2026, 10:30 AM EDT
Completed Not applicable Interventional Results available

Piloting the IPROACTIF Program to Preserve Functioning and Prevent Cognitive Decline

NCT04682977
View directory record Official record
Conditions
Heart Disease (Coronary Artery Disease, Ischemic Heart Disease, Hypertensive Heart Disease), Uncontrolled Diabetes (HBA1c ≥ 10)
Interventions
IPROACTIF (Integrated PRimary Care and Occupational Therapy for Aging and Chronic Disease Treatment to preserve Independence and Functioning), Usual primary care services
Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
55 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 18, 2025 · Synced Jul 21, 2026, 10:30 AM EDT
Terminated Phase 3 Interventional

Effects of Pulsed Intravenous (IV) Insulin on Brittle and Uncontrolled Diabetes

NCT01029444
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Pulsatile Intravenous Insulin Therapy (Humulin, Humulog, Novolog )
Procedure
Lead sponsor
Florida Atlantic University
Other
Eligibility
18 Years to 85 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Feb 2, 2016 · Synced Jul 21, 2026, 10:30 AM EDT